Biophytis S.A.

Earnings Release • Dec 4, 2015

Press release

BIOPHYTIS: HALF-YEAR RESULTS FOR 2015

Paris (France) & Cambridge (Mass), 4 December 2015 – Biophytis (Alternext Paris: ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), announced today financial results for the six months ended June 30, 2015, prepared under IFRS.

Stanislas Veillet, CEO of BIOPHYTIS commented: "During the first half of the year 2015, we successfully completed the IPO of the Company in Paris. We are now totally focused on preparing two Phases 2b trials : Sarcob for sarcopenic obesity and Maculia for dry AMD – indications for which there is important unmet need and for which no suitable therapies are currently available.".

«The IPO and subsequent private placement allowed us to raise capital and acquire intellectual property critical to the creation of shareholder value», added Jean-Christophe Montigny, CFO. «With the cash in hand, the Company can complete ongoing preparations for Phase IIb trials for both of our lead products.»

Summary of the key financial figures for the first half of 2015 (IFRS standards):

In Euros – IFRS	June 30, 2015	June 30, 2014
Operating income	-	-
Research & Development expenses	400 304	430 942
Public funding & other Products	134 301	315 463
General and Administrative expenses	603 596	196 232
Current operating result	(869 599)	(311 710)
Financial result	(125 750)	(14 721)
Net result	(995 350)	(326 431)

• The net Result amounted to a loss of €995,350 as of June 30, 2015, compared with (€326,431) as of June 30, 2014.
• R&D expenditures were similar with regards to the same period of 2014.
• General and Administrative expenses increased by €408,000 compared to the first half of 2014, primarily due to fees associated with the IPO.
• As of June 30, 2015, the closing treasury and cash equivalents amounted to €1,6 million versus €81 thousand a year earlier. The increase cash was due to the issue of bonds during the first half of 2015, totalling €1,7 million.

Key post-closure events:

July 2015: Initial public offering of the Company on Euronext's Alternext, Paris segment. Biophytis issued 1,672,500 new shares, trading under the ticker ALBPS, at a price of 6 euros per share corresponding a €10 million capital increase, including the purchase of intellectual property. The shares began trading on July 13, 2015.

August 2015: The Company realized a private placement in public equity with an undisclosed North American investor, raising

an additional €6 million through the issuance of 666,700 new shares.

September 2015: Biophytis announced that it had begun production of the clinical batches of Sarcob BIO101 with the american group Patheon, for future clinical trials in to treat sarcopnic obesity.

Novembre 2015 : Biophytis established a U.S. subsidiary in Boston, Mass., to accelerate clinical development and facilitate relationships with leading U.S. biotech and pharmaceutical companies.

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry age-related macular degeneration (AMD).

The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is eligible for the French PEA-PME regime.

Biophytis Stanislas Veillet CEO contact@biophytis.com Tel : +33 1 41 83 66 00

Milestones Bruno Arabian barabian@milestones.fr Tel : +33 1 83 62 34 84 Mob : +33 6 87 88 47 26 LifeSci Advisors Chris Maggos Managing Director, Europe chris@lifesciadvisors.com Tel : +41 79 367 6254